MedTrace Logo

DC Vaccination for Post-remission Therapy in AML

NCT02405338 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-07-07

No results posted yet for this study

Summary

This is a multi-centre, open label, prospective, non-randomized phase I/II trial in 20 patients including a safety-run in phase I part comprising 6 patients.

Trial subjects will receive repeated immunotherapies with autologous Dendritic Cells (DCs), presenting two leukemia-associated antigens.

Conditions

Interventions

BIOLOGICAL

WT1/PRAME vaccination

Sponsors & Collaborators

  • Medigene AG

    lead INDUSTRY

Principal Investigators

  • Yngvar Fløisand · Oslo University Hospital, Rikshospitalet Department of Hematology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02405338 on ClinicalTrials.gov